Abbvie
Coverage of Abbvie in the Nexus archive.
- Congress is investigating Merck and AbbVie over drug trials in China tied to its military
Congress is investigating Merck and AbbVie over clinical trials conducted in China, specifically at military facilities and in Xinjiang. A bipartisan House committee has requested details on hundreds of these studies.
- FDA Expands Risankizumab Label in Psoriatic Disease
The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older. AbbVie announced this update, noting risankizumab is an interleukin (IL)-23 antagonist.
- Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly, and Johnson & Johnson were on track to hit all-time highs Friday, signaling renewed investor interest in the biopharmaceutical sector. Healthcare stocks are becoming a refuge for investors shifting away from technology stocks.
- America’s Split Economy: The Boom and the Worker
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in a debt-funded deal, offering a 49% premium over Apogee’s June 18 closing share price. The transaction reflects a long-term investment in the company’s future growth.
- US stocks drift near their records in mixed trading after oil prices fall
U.S. stocks traded near records with mixed performance as oil prices fell following U.S.-Iran talks over the war. The S&P 500 declined 0.3%, the Dow rose 0.3%, and the Nasdaq dropped 1%. Lower oil prices did not reduce Treasury yields, which climbed amid inflation concerns and speculation about Federal Reserve rate hikes.
- US stocks drift near their records after oil prices fall
US stocks edged near records amid falling oil prices following US-Iran talks over the war, which could ease Strait of Hormuz tensions. The S&P 500 and Dow rose slightly, while the Nasdaq dipped. Treasury yields climbed due to inflation concerns, with traders anticipating potential Fed rate hikes by year-end.
- AbbVie is buying an eczema and asthma drug developer for almost $11 billion
AbbVie is acquiring a drug developer for nearly $11 billion in cash to gain access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis.
- AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
AbbVie acquired Apogee for $10.9 billion to gain an inflammatory disease drug. The deal is AbbVie's largest in over five years and reflects increased M&A activity in the pharmaceutical sector.
- STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, valuing the company at $135.11 per share, a 50% premium over its previous closing price. The deal focuses on Apogee's lead drug, zumilokibart, which targets IL-13 and is being tested for inflammatory diseases like atopic dermatitis and asthma.
- AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly attempting to acquire a biotech company developing a promising atopic dermatitis drug for $10.9 billion in cash, as per a Financial Times report.
- Platner’s anti-corporate crusade hits awkward snag as receipts tell another story
Maine Senate candidate Graham Platner, known for criticizing corporations like Big Pharma, accepted over $30,000 in donations from lobbyists and executives representing those industries between August 2025 and March. Despite pledging to reject contributions over $200 from healthcare industry affiliates, Platner received $1,000 each from lobbyists working for AbbVie, Novartis, and Moderna, though one donation was later returned.
- Platner’s anti-corporate crusade hits awkward snag as receipts tell another story
Graham Platner, a Maine Senate candidate, faces scrutiny for accepting over $30,000 from lobbyists and executives at major corporations while campaigning against big tech, pharmaceuticals, banks, and defense contractors. Despite pledging to reject contributions over $200 from healthcare industry lobbyists, Platner received $1,000 donations from lobbyists representing AbbVie, Novartis, and Moderna prior to making the pledge.
- STAT+: An AI biotech CEO sets the record straight on AI drug development hype
Peyton Greenside, CEO of BigHat Biosciences, critiques the hype around AI-driven drug development, emphasizing that while AI can rapidly design proteins, the actual drug-making process remains time-consuming and costly. The company, founded in 2019, partners with major pharmaceutical firms like Johnson & Johnson, Merck, and Amgen.
- Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
Sen. John Cornyn questioned AbbVie CEO Richard Gonzalez during a 2019 congressional hearing about the company's 136 patents on Humira, a drug with the same active molecule used to treat multiple conditions. Gonzalez defended the patents as 'innovations,' extending patent protection beyond the original 2016 expiry. The exchange highlights concerns about pharmaceutical companies leveraging patent portfolios to maintain monopolies.
- Novo Nordisk lets Canadian patent expire
Generic versions of Ozempic entered the Canadian market after Novo Nordisk allowed its patent to expire, possibly due to failing to pay a $250 filing fee. The move raises questions about whether this was strategic corporate planning or an expensive oversight, as it allows generics to compete while potentially avoiding statutory price caps on patented drugs.